Course of obesity and extreme obesity in adolescents, in the context of different treatment options - a longitudinal prospective observation study

Course of obesity and extreme obesity in adolescents, in the context of different treatment options - a longitudinal prospective observation study - YES

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00004198

Enrollment

600

Registered

2012-07-20

Start date

2012-07-23

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E66

Interventions

Group 1: Adolescents with extreme obesity (BMI =35kg/m2). Adolescent will be examined annually (initially biannually), and testing will include an array of standardized questionnaires and validated in

Eligibility

Sex/Gender

All

Age

14 Years to 24 Years

Inclusion criteria

Inclusion criteria: BMI = 30.0 kg/m2, adequate German language skills

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Adherence with structured care. The percentage of subjects that comply with the structured follow up program will be calculated once a year.	—

Secondary

Measure	Time frame
1. Percentage of subjects that can be integrated into the job-market or into an apprenticeship training position. Integration into the job marked or educational programs will be determined via standardized questionnaire (modified after KIGGS and TeenLABS) once a year. 2. Percentage of subjects that undergo the recommended diagnostic procedures. Medically appropriate diagnostic procedures will be recommended to the patients, and the percentage of subjects that undergo all procedures will be determined at each follow up. 3. Incidences and changes of somatic co-morbidities. Presence and severity of somatic co-morbidities will be assessed via standardized physical examination, laboratory and apparative tests, and standardized patient questionnaires (modified after KIGGS and TeenLABS) at each follow up. 4. Incidences and changes of psychiatric co-morbidities. Presence and severity of psychiatric co-morbidities will be assessed via validated patient questionnaires once a year. 5. Compliance with treatment of somatic co-morbidities. Appropriate treatment of the diagnosed somatic co-morbidities will be offered to all subjects. The percentage of subjects who comply with such therapy will be assessed via standardized questionnaire (modified after KIGGS and TeenLABS) at each follow up. 6. Compliance with treatment of psychiatric co-morbidities. Appropriate treatment of the diagnosed psychiatric co-morbidities will be offered to all subjects. The percentage of subjects who comply with such therapy will be assessed via standardized questionnaire (modified after KIGGS and TeenLABS) at each follow up. 7. Health related quality of life. Health related quality of life will be assessed via validated questionnaires (EQ5D, DISABKIDS) once a year. 8. Socio-economic status. Socio-economic status will be assessed via standardized questionnaires (modified after KIGGS and TeenLABS) once a year. 9. The incidence of extreme obesity (BMI =35kg/m2) will be determined in the group of a	—

Measure

Time frame

1. Percentage of subjects that can be integrated into the job-market or into an apprenticeship training position. Integration into the job marked or educational programs will be determined via standardized questionnaire (modified after KIGGS and TeenLABS) once a year. 2. Percentage of subjects that undergo the recommended diagnostic procedures. Medically appropriate diagnostic procedures will be recommended to the patients, and the percentage of subjects that undergo all procedures will be determined at each follow up. 3. Incidences and changes of somatic co-morbidities. Presence and severity of somatic co-morbidities will be assessed via standardized physical examination, laboratory and apparative tests, and standardized patient questionnaires (modified after KIGGS and TeenLABS) at each follow up. 4. Incidences and changes of psychiatric co-morbidities. Presence and severity of psychiatric co-morbidities will be assessed via validated patient questionnaires once a year. 5. Compliance with treatment of somatic co-morbidities. Appropriate treatment of the diagnosed somatic co-morbidities will be offered to all subjects. The percentage of subjects who comply with such therapy will be assessed via standardized questionnaire (modified after KIGGS and TeenLABS) at each follow up. 6. Compliance with treatment of psychiatric co-morbidities. Appropriate treatment of the diagnosed psychiatric co-morbidities will be offered to all subjects. The percentage of subjects who comply with such therapy will be assessed via standardized questionnaire (modified after KIGGS and TeenLABS) at each follow up. 7. Health related quality of life. Health related quality of life will be assessed via validated questionnaires (EQ5D, DISABKIDS) once a year. 8. Socio-economic status. Socio-economic status will be assessed via standardized questionnaires (modified after KIGGS and TeenLABS) once a year. 9. The incidence of extreme obesity (BMI =35kg/m2) will be determined in the group of a

—

Countries

Germany

Contacts

Public ContactMartin Wabitsch

Sektion Pädiatrische Endokrinologie und Diabetologie, Universitätsklinik für Kinder- und Jugendmedizin

stephanie.brandt@uniklinik-ulm.de0731 500 57401

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026